Gastrointestinal perforation associated with bevacizumab in metastatic colorectal cancer
Cancer Reports · 2024
DOI: 10.1002/cnr2.1952 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Reports, 2024. Verfasst von Kunpeng Fang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Special Treatment I, Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital), Shanghai, China. Hauptthemen laut MEDLINE: Intestinal Perforation, Colorectal Neoplasms, Rectal Neoplasms, Colonic Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Program of Science and Technology Commission of Shanghai Municipality.
Abstract (Originalsprache)
Objective
To investigate the risk factors for gastrointestinal perforation in metastatic colorectal cancer patients receiving bevacizumab.
Methods
We retrospectively reviewed 217 patients with metastatic colorectal cancer receiving bevacizumab to investigate the risk factors for gastrointestinal perforation. Three patients occurred intestinal perforation after receiving bevacizumab. We analyzed the clinical characteristics of three patients with intestinal perforation.
Results
All patients receiving bevacizumab. Three of 217 patients occurred intestinal perforation after receiving bevacizumab. Patient no. 1 was 70 years old, female, having history of intestinal obstruction. The patient occurred intestinal perforation and ultimately died after receiving bevacizumab. Patient no. 2 was 59 years old, female, having history of intestinal obstruction. The patient occurred intestinal perforation after receiving bevacizumab, and recovered smoothly after symptomatic treatment. Patient no. 3 was 60 years old, female, having history of intestinal obstruction. The patient occurred intestinal perforation and ultimately died after receiving bevacizumab.
Conclusions
Patients with advanced colorectal cancer receiving bevacizumab are at risk of gastrointestinal perforation. The patient's age, gender and history of bowel obstruction may be associated with gastrointestinal perforation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Special Treatment I, Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital), Shanghai, China.
- Department of Hepatic Surgery II, Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital), Shanghai, China.
- Hepatobiliary Pancreatic Surgery, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
- Department of Colorectal and Anal Surgery, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Hepatic Surgery IV, Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital), Shanghai, China.
- Department of Hepatic Surgery I, Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital), Shanghai, China.
Förderung
- the Program of Science and Technology Commission of Shanghai Municipality
Zitieren
APA
Fang, K., Wang, J., Yuan, J., Sui, C., Zhi, J., Xia, Y., & Sun, M. (2024). Gastrointestinal perforation associated with bevacizumab in metastatic colorectal cancer. Cancer Reports. https://doi.org/10.1002/cnr2.1952
Vancouver
Fang K, Wang J, Yuan J, Sui C, Zhi J, Xia Y, et al. Gastrointestinal perforation associated with bevacizumab in metastatic colorectal cancer. Cancer Reports. 2024. doi:10.1002/cnr2.1952
BibTeX
@article{Fang2024,
author = {Fang, Kunpeng and Wang, Jie and Yuan, Jianyong and Sui, Chengjun and Zhi, Jiajun and Xia, Yong and Sun, Minmin},
title = {Gastrointestinal perforation associated with bevacizumab in metastatic colorectal cancer},
journal = {Cancer Reports},
year = {2024},
doi = {10.1002/cnr2.1952}
}
EUVIMED